Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Paul Bunn to Neoplasm Staging

This is a "connection" page, showing publications Paul Bunn has written about Neoplasm Staging.

 
Connection Strength
  
 
 
1.943
  
  1. Bunn PA. Optimal therapy for elderly patients with early stage non-small cell lung cancer. Am J Respir Crit Care Med. 2010 Feb 01; 181(3):201-2.
    View in: PubMed
    Score: 0.270
  2. Bunn PA, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clin Lung Cancer. 2015 Jul; 16(4):245-51.
    View in: PubMed
    Score: 0.096
  3. Bunn PA, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res. 2014 Apr 01; 20(7):1727-9.
    View in: PubMed
    Score: 0.090
  4. Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. J Clin Oncol. 2014 Apr 01; 32(10):973-82.
    View in: PubMed
    Score: 0.090
  5. Bunn PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. Arch Pathol Lab Med. 2012 Dec; 136(12):1478-81.
    View in: PubMed
    Score: 0.082
  6. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25.
    View in: PubMed
    Score: 0.063
  7. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42.
    View in: PubMed
    Score: 0.060
  8. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist. 2008; 13 Suppl 1:1-4.
    View in: PubMed
    Score: 0.059
  9. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008; 13 Suppl 1:37-46.
    View in: PubMed
    Score: 0.059
  10. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60.
    View in: PubMed
    Score: 0.055
  11. Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
    View in: PubMed
    Score: 0.046
  12. Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
    View in: PubMed
    Score: 0.046
  13. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002 Sep 15; 20(18 Suppl):23S-33S.
    View in: PubMed
    Score: 0.041
  14. Bunn PA. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer]. Anticancer Drugs. 2001 Jul; 12 Suppl 3:S3-8.
    View in: PubMed
    Score: 0.037
  15. Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S.
    View in: PubMed
    Score: 0.034
  16. Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S.
    View in: PubMed
    Score: 0.034
  17. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 2000 Mar; 119(3):429-39.
    View in: PubMed
    Score: 0.034
  18. Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24.
    View in: PubMed
    Score: 0.033
  19. Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, Robin T, Liu A, Karam S, Gaspar L, Kavanagh B, Rusthoven C, Aisner D, Doebele R, Camidge DR. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 04; 14(4):691-700.
    View in: PubMed
    Score: 0.031
  20. Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 11; 13(11):1717-1726.
    View in: PubMed
    Score: 0.030
  21. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100.
    View in: PubMed
    Score: 0.030
  22. Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67.
    View in: PubMed
    Score: 0.029
  23. Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Bar?n AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 01; 13(1):134-138.
    View in: PubMed
    Score: 0.029
  24. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
    View in: PubMed
    Score: 0.028
  25. Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 06; 96:27-32.
    View in: PubMed
    Score: 0.026
  26. Bunn PA, Kelly KL. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60.
    View in: PubMed
    Score: 0.025
  27. Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6.
    View in: PubMed
    Score: 0.025
  28. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul; 13(7):1632-41.
    View in: PubMed
    Score: 0.025
  29. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777.
    View in: PubMed
    Score: 0.024
  30. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
    View in: PubMed
    Score: 0.023
  31. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol. 1994 Jun; 21(3 Suppl 6):49-59.
    View in: PubMed
    Score: 0.023
  32. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309.
    View in: PubMed
    Score: 0.023
  33. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
    View in: PubMed
    Score: 0.021
  34. Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
    View in: PubMed
    Score: 0.020
  35. Hazuka MB, Bunn PA. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Respir Dis. 1992 Apr; 145(4 Pt 1):967-77.
    View in: PubMed
    Score: 0.020
  36. Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S.
    View in: PubMed
    Score: 0.018
  37. Bunn PA. Operation for stage IIIa small cell lung cancer? Ann Thorac Surg. 1990 May; 49(5):691.
    View in: PubMed
    Score: 0.017
  38. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010 May 01; 28(13):2174-80.
    View in: PubMed
    Score: 0.017
  39. Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
    View in: PubMed
    Score: 0.017
  40. Bunn PA. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol. 1989 Aug; 16(4 Suppl 6):10-21.
    View in: PubMed
    Score: 0.016
  41. Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr; 16(2 Suppl 5):27-33.
    View in: PubMed
    Score: 0.016
  42. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
    View in: PubMed
    Score: 0.015
  43. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.014
  44. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535.
    View in: PubMed
    Score: 0.013
  45. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 01; 24(13):2038-43.
    View in: PubMed
    Score: 0.013
  46. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
    View in: PubMed
    Score: 0.013
  47. Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Cancer Treat Rep. 1984 Dec; 68(12):1439-46.
    View in: PubMed
    Score: 0.012
  48. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46.
    View in: PubMed
    Score: 0.012
  49. Winkler CF, Bunn PA. Cutaneous T-cell lymphoma: a review. Crit Rev Oncol Hematol. 1983; 1(1):49-92.
    View in: PubMed
    Score: 0.010
  50. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS, Bunn PA. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore). 1982 Jan; 61(1):45-53.
    View in: PubMed
    Score: 0.010
  51. Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med. 1980 Aug; 93(2):223-30.
    View in: PubMed
    Score: 0.009
  52. Bunn PA, Carney DN. Treatment of cutaneous T-cell lymphoma. J Dermatol Surg Oncol. 1980 May; 6(5):383-7.
    View in: PubMed
    Score: 0.009
  53. Carney DN, Bunn PA. Manifestations of cutaneous T-cell lymphoma. J Dermatol Surg Oncol. 1980 May; 6(5):369-77.
    View in: PubMed
    Score: 0.009
  54. Bunn PA, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979 Apr; 63(4):725-8.
    View in: PubMed
    Score: 0.008
  55. Pisters KM, Kris MG, Bunn PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-41-S12-44.
    View in: PubMed
    Score: 0.007
  56. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
    View in: PubMed
    Score: 0.006
  57. Lamb R, Gonzalez R, Myers A, Bunn P, Robinson W. Aggressive non-Hodgkin's lymphomas in AIDS: the University of Colorado experience. Am J Med Sci. 1990 Dec; 300(6):345-9.
    View in: PubMed
    Score: 0.004
  58. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989 Dec 28; 321(26):1784-90.
    View in: PubMed
    Score: 0.004
  59. Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):515-39.
    View in: PubMed
    Score: 0.003
  60. Ihde DC, Dunnick NR, Johnston-Early A, Bunn PA, Cohen MH, Minna JD. Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy. Cancer. 1982 Apr 01; 49(7):1485-90.
    View in: PubMed
    Score: 0.002
  61. Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD, Gazdar AF. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13; 1(8272):583-5.
    View in: PubMed
    Score: 0.002
  62. Ihde DC, Makuch RW, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Minna JD. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis. 1981 May; 123(5):500-7.
    View in: PubMed
    Score: 0.002
  63. Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer. 1980 Mar 15; 45(6):1300-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)